EPISODE · Oct 28, 2022 · 13 MIN
Rare Disease Report: The FDA Decision for Pompe Disease Therapy
from HCPLive Podcasts · host HCPLive.com
The FDA is expected to announce the final decision for the dual therapy AT-GAA, which uses miglustat in combination with cipaglucosidase alfa for treating Pompe disease, an inherited and often times fatal disorder. Expert Barry Byrne discusses the characteristics of the condition and what this FDA decision will mean for treatment.
Embed this episode
NOW PLAYING
Rare Disease Report: The FDA Decision for Pompe Disease Therapy
0:00
13:25
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of HCPLive Podcasts?
This episode is 13 minutes long.
When was this HCPLive Podcasts episode published?
This episode was published on October 28, 2022.
Can I download this HCPLive Podcasts episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!